Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prenatal Air Pollution Exposure and Autism Spectrum Disorder in the ECHO Consortium.

Environmental health perspectives·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort.

JAMA network open·2026
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026

Related Experiment Video

Updated: Jun 27, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K

From progression to progress: The future of multiple sclerosis.

Jiwon Oh1, Paul S Giacomini2, V Wee Yong3

  • 1St. Michael's Hospital, Toronto, ON, Canada.

Journal of Central Nervous System Disease
|May 7, 2024
PubMed
Summary

Advances in multiple sclerosis (MS) diagnosis and treatment are ongoing. A Canadian expert panel recommends a shift towards mechanism-based management and personalized medicine for better patient outcomes.

Keywords:
Multiple sclerosisdigital biomarkerdisease progressionfluid biomarkerpathophysiology

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K

Related Experiment Videos

Last Updated: Jun 27, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K

Area of Science:

  • Neurology
  • Immunology
  • Personalized Medicine

Background:

  • Current multiple sclerosis (MS) classifications do not fully capture individual pathophysiological mechanisms driving disease.
  • A need exists to transition MS management towards a mechanism-based approach to better address patient disability progression.

Purpose of the Study:

  • To outline priorities for clinical discovery and scientific exploration in multiple sclerosis (MS).
  • To identify key areas for advancing MS diagnosis, treatment, and prevention strategies.

Main Methods:

  • Convening a Canadian expert panel in January 2023 to discuss MS research and clinical priorities.
  • Identifying five key areas for focus: mechanism-based classification, biomarker development, data integration, precision treatments, and disease prevention.

Main Results:

  • The panel identified critical areas for advancing MS care, including developing a mechanism-based classification system.
  • Priorities include developing diverse biomarkers (imaging, fluid, digital) to identify pathological processes.
  • Integrating multi-modal data (genetics, environment, clinical, imaging, patient outcomes) is crucial for understanding disability progression.

Conclusions:

  • Transitioning to a mechanism-based and personalized medicine approach in MS is essential for improving long-term patient outcomes.
  • Further validation of biomarkers and tailoring treatments to individual patient needs are required.
  • Potential prevention strategies include Epstein-Barr virus (EBV) vaccination and addressing environmental risk factors.